Sean Brynjelsen
Chief Executive Officer chez ETON PHARMACEUTICALS, INC.
Fortune : 4 M $ au 31/03/2024
Profil
Sean E.
Brynjelsen is the President, Chief Executive Officer & Director at Eton Pharmaceuticals, Inc. He was previously the Senior Vice President-Global Business Development at Akorn, Inc. from 2015 to 2016 and the Executive Vice President-Business Development at Sagent Pharmaceuticals, Inc. from 2016 to 2017.
Brynjelsen earned an MBA from the University of Notre Dame in 2006 and completed his undergraduate and graduate degrees at the University of Illinois in 1993 and 1995, respectively.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 13/02/2024 | 1 074 940 ( 4,18% ) | 4 M $ | 31/03/2024 |
Postes actifs de Sean Brynjelsen
| Sociétés | Poste | Début |
|---|---|---|
| ETON PHARMACEUTICALS, INC. | Chief Executive Officer | 01/06/2017 |
Anciens postes connus de Sean Brynjelsen
| Sociétés | Poste | Fin |
|---|---|---|
| SAGENT PHARMACEUTICALS INC | Corporate Officer/Principal | 01/06/2017 |
| AKORN, INC. | Chief Tech/Sci/R&D Officer | 07/02/2014 |
Formation de Sean Brynjelsen
| University of Notre Dame | Masters Business Admin |
| University of Illinois | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ETON PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Akorn, Inc.
 Akorn, Inc. Pharmaceuticals: MajorHealth Technology Akorn, Inc. engages in the development, manufacture, and marketing of generic and prescription pharmaceuticals, and animal and consumer health products. It manufactures and markets branded and generic products including ophthalmic, injectable, oral liquids, topical, inhalants, and nasal sprays. The company was founded in 1971 and is headquartered in Lake Forest, IL. | Health Technology |
Sagent Pharmaceuticals, Inc.
 Sagent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sagent Pharmaceuticals, Inc. engages in the developing, manufacturing, and marketing of medical products. It offers injectable products such as amikacin sulfate, ampicillin and sulbactam, cefazolin, piperacillin and tazobactam, and vancomycin hydrochloride. The company was founded by Jeffrey M. Yordon in 2006 and is headquartered in Schaumburg, IL. | Health Technology |
